Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Latest News

Glaxosmithkline Share Price (GSK)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 1,202.20on 26-02-2021 at 15:04:51
Change -13.80 -1.13%
Buy 1,202.60
Sell 1,202.20
Buy / Sell GSK Shares
Sponsored Financial Content
Last Trade: Buy 250 at 1,202.40p
Day's Volume: 3,966,777
Last Close: 1,216.00p
Open: 1,202.20p
ISIN: GB0009252882
Day's Range 1,202.20p - 1,236.80p
52wk Range: 1,196.00p - 1,742.40p
Market Capitalisation: £60,483m
VWAP: 1,202.719p
Shares in Issue: 5,031m

Recent Trades History Glaxosmithkline (GSK)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy*2501,202.40Automatic Execution
14:50:56 - 26-Feb-21
Sell*2501,202.20Automatic Execution
14:50:52 - 26-Feb-21
Sell*2501,202.20Automatic Execution
14:50:52 - 26-Feb-21
Buy*2461,202.20Automatic Execution
14:50:52 - 26-Feb-21
Sell*2501,202.20Automatic Execution
14:50:52 - 26-Feb-21
Buy*291,202.20Automatic Execution
14:50:52 - 26-Feb-21
Sell*2501,202.20Automatic Execution
14:50:52 - 26-Feb-21
Buy*1,8741,203.00Ordinary
14:50:50 - 26-Feb-21
Buy*161,202.60Automatic Execution
14:50:51 - 26-Feb-21
Buy*3001,202.40Automatic Execution
14:50:51 - 26-Feb-21

Share Price History for Glaxosmithkline

Time period:
to
Date Open High Low Close
24th Feb 2021 (Wed)1,207.401,221.601,199.201,215.20
23rd Feb 2021 (Tue)1,205.401,220.801,196.001,207.70
22nd Feb 2021 (Mon)1,211.201,224.001,201.401,207.70
19th Feb 2021 (Fri)1,225.601,232.801,212.601,219.00
18th Feb 2021 (Thu)1,260.001,260.601,230.201,274.60
17th Feb 2021 (Wed)1,265.801,278.401,260.801,274.60
16th Feb 2021 (Tue)1,289.001,294.401,266.801,269.30
15th Feb 2021 (Mon)1,283.201,292.801,261.401,289.00
12th Feb 2021 (Fri)1,260.201,278.601,253.201,278.20
11th Feb 2021 (Thu)1,275.001,283.001,255.201,258.90
10th Feb 2021 (Wed)1,286.601,291.601,266.201,276.20
9th Feb 2021 (Tue)1,268.401,284.201,265.001,280.30
8th Feb 2021 (Mon)1,275.001,287.801,265.801,274.20
5th Feb 2021 (Fri)1,278.001,292.401,256.401,267.40
4th Feb 2021 (Thu)1,280.001,323.601,277.601,283.90
3rd Feb 2021 (Wed)1,369.601,385.001,287.001,367.10
2nd Feb 2021 (Tue)1,353.201,369.601,349.001,356.00
1st Feb 2021 (Mon)1,360.001,366.801,351.801,356.00
29th Jan 2021 (Fri)1,362.001,373.801,352.201,388.70
28th Jan 2021 (Thu)1,387.801,399.201,377.001,397.90
27th Jan 2021 (Wed)1,412.801,414.201,395.201,412.80
26th Jan 2021 (Tue)1,405.001,423.201,405.001,412.80

GSK - Glaxosmithkline Investor Summary

GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.

If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.

On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.

News about Glaxosmithkline (GSK)

Director Deals - (GSK)

News - Thursday, February 25, 2021

Hal Barron, Executive Director, bought 2,446 shares in the company on the 22nd F......

Director Deals - (GSK)

News - Thursday, February 25, 2021

Hal Barron, Executive Director, bought 438 shares in the company on the 22nd Feb......

FTSE 100 Latest
Value6,519.34
Change-132.62


Login to your account

Forgot Password?

Not Registered